Monocytes and macrophages as nanomedicinal targets for improved diagnosis and treatment of disease
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
The important role of monocytes and macrophages in diseases like cancer and atherosclerosis has started to get uncovered in the last decade. In addition, subsets of these cell types are believed to participate in the initiation and aggravation of several diseases including cancer and cardiovascular disease. For this reason, monocytes and macrophages have recently been identified as interesting targets for both diagnosis and treatment of the aforementioned pathologies. Compared with free therapeutic or imaging agents, nanoparticle formulations provide several advantages that improve the pharmacokinetics and bioavailability of these agents. In addition, the possibility of surface functionalization creates numerous ways to optimize nanoparticle delivery. Recent advances in nanomedicine have led to the development of multifunctional nanoparticles that allow simultaneous diagnosis and treatment of monocytes and macrophages with high specificity. Relying on the inherent ability of monocytes and macrophages to easily take up foreign particles, the use of nanoparticles provides a precious opportunity for the management of several inflammatory diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Protective and pathogenic functions of macrophage subsets
Murray, P. J., & Wynn, T. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri3073 · Cited by 5,269
Progress and challenges in translating the biology of atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2011) · Nature · doi:10.1038/nature10146 · Cited by 4,010
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
Biswas, S. K., & Mantovani, A. (2010) · Nature Immunology · doi:10.1038/ni.1937 · Cited by 3,840
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Fate Mapping Reveals Origins and Dynamics of Monocytes and Tissue Macrophages under Homeostasis
Yona, S., Kim, K.-W., Wolf, Y., Mildner, A., Varol, D., Breker, M., Strauss-Ayali, D., Viukov, S., Guilliams, M., Misharin, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2012.12.001 · Cited by 3,245
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149
Monocyte recruitment during infection and inflammation
Shi, C., & Pamer, E. G. (2011) · Nature Reviews Immunology · doi:10.1038/nri3070 · Cited by 3,015
Macrophages in the Pathogenesis of Atherosclerosis
Moore, K. J., & Tabas, I. (2011) · Cell · doi:10.1016/j.cell.2011.04.005 · Cited by 2,669
Nahrendorf, M., Swirski, F. K., Aikawa, E., Stangenberg, L., Wurdinger, T., Figueiredo, J.-L., Libby, P., Weissleder, R., & Pittet, M. J. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070885 · Cited by 2,300
Self-citationIdentification of splenic reservoir monocytes and their deployment to inflammatory sites
Swirski, F. K., Nahrendorf, M., Etzrodt, M., Wildgruber, M., Cortez-Retamozo, V., Panizzi, P., Figueiredo, J.-L., Kohler, R. H., Chudnovskiy, A., Waterman, P., et al. (2009) · Science · doi:10.1126/science.1175202 · Cited by 2,221
Self-citationNanomedicine: current status and future prospects
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005) · The FASEB Journal · doi:10.1096/fj.04-2747rev · Cited by 2,029
Micellar Nanocarriers: Pharmaceutical Perspectives
Torchilin, V. P. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9132-0 · Cited by 1,910
Mechanisms of Pancreatic β-Cell Death in Type 1 and Type 2 Diabetes
Cnop, M., Welsh, N., Jonas, J.-C., Jörns, A., Lenzen, S., & Eizirik, D. L. (2005) · Diabetes · doi:10.2337/diabetes.54.suppl_2.s97 · Cited by 1,491
Macrophages: master regulators of inflammation and fibrosis
Wynn, T., & Barron, L. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1255354 · Cited by 1,392
Tacke, F., Alvarez, D., Kaplan, T. J., Jakubzick, C., Spanbroek, R., Llodra, J., Garin, A., Liu, J., Mack, M., van Rooijen, N., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28549 · Cited by 1,323
Stout, R. D., Jiang, C., Matta, B., Tietzel, I., Watkins, S. K., & Suttles, J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.1.342 · Cited by 968
Macrophages in skin injury and repair
Delavary, B. M., van der Veer, W. M., van Egmond, M., Niessen, F. B., & Beelen, R. H. J. (2011) · Immunobiology · doi:10.1016/j.imbio.2011.01.001 · Cited by 922
Self-citationMacrophage activation switching: an asset for the resolution of inflammation
Porcheray, F., Viaud, S., Rimaniol, A.-C., Léone, C., Samah, B., Dereuddre-Bosquet, N., Dormont, D., & Gras, G. (2005) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2005.02934.x · Cited by 840
Therapeutic siRNA silencing in inflammatory monocytes in mice
Leuschner, F., Dutta, P., Gorbatov, R., Novobrantseva, T. I., Donahoe, J. S., Courties, G., Lee, K. M., Kim, J. I., Markmann, J. F., Marinelli, B., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1989 · Cited by 839
Self-citation“Re-educating” tumor-associated macrophages by targeting NF-κB
Hagemann, T., Lawrence, T., McNeish, I., Charles, K. A., Kulbe, H., Thompson, R. G., Robinson, S. C., & Balkwill, F. R. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080108 · Cited by 792
Kadl, A., Meher, A. K., Sharma, P. R., Lee, M. Y., Doran, A. C., Johnstone, S. R., Elliott, M. R., Gruber, F., Han, J., Chen, W., et al. (2010) · Circulation Research · doi:10.1161/circresaha.109.215715 · Cited by 573
Ahsan, F. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00549-1 · Cited by 570
Nanoparticle PET-CT Imaging of Macrophages in Inflammatory Atherosclerosis
Nahrendorf, M., Zhang, H., Hembrador, S., Panizzi, P., Sosnovik, D. E., Aikawa, E., Libby, P., Swirski, F. K., & Weissleder, R. (2008) · Circulation · doi:10.1161/circulationaha.107.741181 · Cited by 559
Self-citationMigratory fate and differentiation of blood monocyte subsets
Tacke, F., & Randolph, G. J. (2006) · Immunobiology · doi:10.1016/j.imbio.2006.05.025 · Cited by 528
Weinstein, J. S., Varallyay, C. G., Dosa, E., Gahramanov, S., Hamilton, B., Rooney, W. D., Muldoon, L. L., & Neuwelt, E. A. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.192 · Cited by 500
Perspectives and opportunities for nanomedicine in the management of atherosclerosis
Lobatto, M. E., Fuster, V., Fayad, Z. A., & Mulder, W. J. M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3578 · Cited by 423
Self-citationMonocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease
Swirski, F. K., Pittet, M. J., Kircher, M. F., Aikawa, E., Jaffer, F. A., Libby, P., & Weissleder, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604260103 · Cited by 367
Nanocrystal Core High-Density Lipoproteins: A Multimodality Contrast Agent Platform
Cormode, D. P., Skajaa, T., van Schooneveld, M. M., Koole, R., Jarzyna, P., Lobatto, M. E., Calcagno, C., Barazza, A., Gordon, R. E., Zanzonico, P., et al. (2008) · Nano Letters · doi:10.1021/nl801958b · Cited by 328
Self-citationGautier, E. L., Jakubzick, C., & Randolph, G. J. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.180505 · Cited by 216
Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients
Gaglia, J. L., Guimaraes, A. R., Harisinghani, M., Turvey, S. E., Jackson, R., Benoist, C., Mathis, D., & Weissleder, R. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44339 · Cited by 209
Targeting monocytes/macrophages in the treatment of rheumatoid arthritis
Davignon, J.-L., Hayder, M., Baron, M., Boyer, J.-F., Constantin, A., Apparailly, F., Poupot, R., & Cantagrel, A. (2013) · Rheumatology · doi:10.1093/rheumatology/kes304 · Cited by 209
Lobatto, M. E., Fayad, Z. A., Silvera, S., Vucic, E., Calcagno, C., Mani, V., Dickson, S. D., Nicolay, K., Banciu, M., Schiffelers, R. M., et al. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100309y · Cited by 170
Self-citationMcCarthy, J. R., Korngold, E., Weissleder, R., & Jaffer, F. A. (2010) · Small · doi:10.1002/smll.201000596 · Cited by 151
Cited by
Nanoparticle targeting of de novo profibrotic macrophages mitigates lung fibrosis
Singh, A., Chakraborty, S., Wong, S. W., Hefner, N. A., Stuart, A., Qadir, A. S., Mukhopadhyay, A., Bachmaier, K., Shin, J.-W., Rehman, J., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2121098119 · Cited by 107
Jia, C., Chen, H., Wei, M., Chen, X., Zhang, Y., Cao, L., Yuan, P., Wang, F., Yang, G., & Ma, J. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s138400 · Cited by 106
“32,33 AuNP is an ideal material for nucleic acid delivery.”
Huang, Y.-J., Hung, K.-C., Hung, H.-S., & Hsu, S.-H. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b04718 · Cited by 89
Prediction of anti-cancer nanotherapy efficacy by imaging
Miller, M. A., Arlauckas, S., & Weissleder, R. (2017) · Nanotheranostics · doi:10.7150/ntno.20564 · Cited by 74
Yamagishi, T., Fujimoto, N., Nishi, H., Miyamoto, Y., Hara, N., Asano, M., Fuchimoto, Y., Wada, S., Kitamura, K., Ozaki, S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.07.014 · Cited by 61
“The combination strategy, which targets cancer cells directly, as well as macrophages and monocytes, may present a potentially new therapeutic approach [39].”
Background
Metadata
- Authors
- Lameijer, M. A., Tang, J., Nahrendorf, M., Beelen, R. H. J., & Mulder, W. J. M.
- Venue
- Expert Review of Molecular Diagnostics
- Publisher
- Informa UK Limited
- Published
- 2013-07
- Volume
- 13
- Issue
- 6
- Pages
- 567-580
- ISSN
- 1473-7159 (ISSN-L)
- 1744-8352
- OpenAlex
- W1971048836
- Cited by
- 97
- References
- 34
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.